

Isolation of high avidity cancer-specific TCRs



PRINCIPLE INVESTIGATOR:
PD. Dr. Antonia Busse, Dr. Martin Klatt
BIH/Charité



SUMMARY

CAR T cells have been very successful in the treatment of hematologic malignancies, but many tumor-specific antigens are expressed intracellularly and cannot be targeted by conventional CAR T cells.

This project seeks to develop a novel adoptive cell therapy with a T cell receptor (TCR) against an HLA-A2 restricted epitope of a cancer germline antigen. High avidity cancer-specific TCRs will be isolated and preclinically characterized *in vitro* and *in vivo*.

PROJECT GOALS

- Isolation and *in vitro* evaluation of high avidity cancer-specific TCRs
- Preclinical development *in vitro* & *in vivo* completed

LONG-TERM GOALS

- Perform phase I clinical trial
- License to Biotech / Pharma or Startup foundation